The Latest Cardiac and Vascular News
BOLT-DVT, a recent prospective, multicenter Investigational Device Exemption (IDE) trial, demonstrated first-line use of computer assisted vacuum thrombectomy (CAVT) for DVT is safe and effective ALAMEDA, Calif., Oct. 20, 2026 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced that the U.S. Food and Drug Administration (FDA) […]
FAIRFAX, Va., Oct. 31, 2025 /PRNewswire/ — A new review of Medicare data shows a marked increase for both arterial and venous thrombectomy claims for venous thromboembolic disease filed between 2017–2022. Researchers analyzed a sampling of arterial and venous thrombectomy Medicare claims…
IRVINE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced planned enrollment of the DEFIANCE trial. DEFIANCE is a randomized controlled trial (“RCT”) comparing […]
11F mechanical thrombectomy system removes large blood clots in deep vein thrombosis (DVT) HALLANDALE BEACH, Flo., Jan. 22, 2021 /PRNewswire/ — Control Medical Technology announced the FDA cleared Control 11F Mechanical Thrombectomy system was used to remove large blood clots from patients with deep vein thrombosis (DVT). “Control removed large blood […]
Study to Enroll Subjects at up to 35 Sites Across the U.S. and Europe DUBLIN – January 26, 2018 – Medtronic plc (NYSE: MDT) today announced the initiation of its investigational device exemption (IDE) study for the Abre(TM) venous self-expanding stent system. The ABRE IDE Study will evaluate the safety and […]
DUBLIN, Ohio, July 30, 2017 /PRNewswire/ — Cardinal Health (NYSE: CAH) today announced that it has completed the acquisition of Medtronic’s Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency business for $6.1 billion. The acquisition was funded with a combination of $4.5 billion in new senior unsecured notes, existing cash and borrowings under our existing credit […]
